Paradox Immunotherapeutics Incorporated

Published purpose

AL amyloidosis is a life-threatening disease caused by the misfolding of free immunoglobulin light chains (LC) which deposit as light chain amyloid (AL) in the heart, kidney, and nervous system, causing organ failure and death. There are currently no existing therapies that direct remove these deposits from organs. We have identified a murine monoclonal antibody, LX-96, that specifically binds to misfolded and aggregated light chains of the kappa isotype, while ignoring the native light chain or intact immunoglobulins. The goal of this project is to humanize murine LX-96 and select a humanized developmental candidate for downstream manufacturing and IND-enabling toxicity studies through in-house and commercial screening assays.